PBM Act
Summary
The PBM Act (S. 4509) prohibits common ownership of pharmacy benefit managers and pharmacies, directly targeting CVS Health, UnitedHealth Group, and Cigna. At an early legislative stage, near-term probability is low, but if enacted, would force major divestitures and reshape the healthcare supply chain.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The PBM Act targets vertical integration of PBMs and pharmacies, with CVS and UnitedHealth most at risk.
- 2.No funding is involved; it is a structural prohibition requiring divestiture.
- 3.Early stage legislation with low near-term probability but significant long-term implications for the healthcare sector.
Market Implications
The PBM Act introduces a clear bearish catalyst for CVS and UnitedHealth, as their vertical integration is directly challenged. Without real market data, the focus should be on the legislative process: if the bill gains cosponsors or advances to markup, expect headline risk and potential valuation compression. For Cigna, the impact is smaller but still notable. In contrast, independent pharmacy chains like Walgreens ($WBA) may see relative outperformance if the bill reduces PBM steering to captive pharmacies, though this is peripheral.
Full Analysis
On May 13, 2026, Sen. Warren introduced the Patients Before Monopolies Act (PBM Act, S. 4509) to separate pharmacy benefit managers (PBMs) from pharmacies under common ownership. The bill was read twice and referred to the Senate Judiciary Committee. The legislation is in an early stage with no committee action yet. It does not authorize any spending—it is a structural prohibition, not a funding bill.
The primary targets are vertically integrated health conglomerates that own both a PBM and a large pharmacy network. CVS Health (Caremark PBM + CVS Pharmacy) is the most exposed, followed by UnitedHealth Group (Optum Rx PBM + Optum Pharmacy). Cigna (Express Scripts PBM + Evernorth specialty pharmacy) has moderate exposure. Independent pharmacies and chains without PBM ownership (e.g., Walgreens, Rite Aid) would face less direct impact and could benefit from reduced steering to affiliated pharmacies.
Market reaction has been muted given the early stage, but the bill adds legislative overhang. For retail investors, the key risk is a forced divestiture scenario: CVS and UNH would likely be required to spin off either their PBM or pharmacy assets, eliminating cross-selling synergies and potentially unlocking value in separate entities but creating near-term operational disruption. The legislative path requires committee markup, Senate floor vote, House passage, and presidential action—unlikely before the 2026 midterm elections. However, growing bipartisan scrutiny of PBMs (cosponsors include both Democrats and Republicans) suggests this issue has staying power.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Prohibition on common ownership of PBM and pharmacy operations
Who must act
CVS Health (owns Caremark PBM and CVS Pharmacy retail chain)
What happens
Forced divestiture of either PBM or pharmacy assets, eliminating vertical integration synergies and market power
Stock impact
CVS derives ~70% of revenue from PBM (Caremark) and retail pharmacy; separation would dismantle cross-subsidization and potentially reduce profitability in both segments
What the bill does
Prohibition on common ownership of PBM and pharmacy operations
Who must act
UnitedHealth Group (owns Optum Rx PBM and Optum Pharmacy, including mail-order and specialty pharmacies)
What happens
Forced divestiture of Optum Rx or Optum Pharmacy, severing vertically integrated pharmacy benefit and pharmacy services
Stock impact
Optum contributes ~40% of UNH's revenue; the PBM and pharmacy operations are key to Optum's value proposition; divestiture would reduce competitive advantage in managing drug costs
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.